Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 225 articles:
HTML format
Text format



Single Articles


    January 2018
  1. AGAH E, Zardoui A, Saghazadeh A, Ahmadi M, et al
    Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0190252.
    PubMed     Text format     Abstract available


  2. WANG C, Klistorner A, Ly L, Barnett MH, et al
    White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques.
    PLoS One. 2018;13:e0191131.
    PubMed     Text format     Abstract available


  3. LAVTAR P, Rudolf G, Maver A, Hodzic A, et al
    Association of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis.
    PLoS One. 2018;13:e0190601.
    PubMed     Text format     Abstract available


  4. BEGGS CB, Giaquinta A, Veroux M, De Marco E, et al
    Mid-term sustained relief from headaches after balloon angioplasty of the internal jugular veins in patients with multiple sclerosis.
    PLoS One. 2018;13:e0191534.
    PubMed     Text format     Abstract available


  5. CALOCER F, Dejardin O, Droulon K, Launoy G, et al
    Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.
    PLoS One. 2018;13:e0191646.
    PubMed     Text format     Abstract available


  6. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Correction: Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2018;13:e0192317.
    PubMed     Text format     Abstract available


  7. DE FLON P, Soderstrom L, Laurell K, Dring A, et al
    Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.
    PLoS One. 2018;13:e0192516.
    PubMed     Text format     Abstract available


  8. HASSANI A, Corboy JR, Al-Salam S, Khan G, et al
    Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.
    PLoS One. 2018;13:e0192109.
    PubMed     Text format     Abstract available


  9. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility.
    PLoS One. 2018;13:e0190043.
    PubMed     Text format     Abstract available


  10. DENNISON L, Brown M, Kirby S, Galea I, et al
    Do people with multiple sclerosis want to know their prognosis? A UK nationwide study.
    PLoS One. 2018;13:e0193407.
    PubMed     Text format     Abstract available


  11. KHAN A, Kamran S, Ponirakis G, Akhtar N, et al
    Peripheral neuropathy in patients with multiple sclerosis.
    PLoS One. 2018;13:e0193270.
    PubMed     Text format     Abstract available


  12. BAGNATO F, Hametner S, Boyd E, Endmayr V, et al
    Untangling the R2* contrast in multiple sclerosis: A combined MRI-histology study at 7.0 Tesla.
    PLoS One. 2018;13:e0193839.
    PubMed     Text format     Abstract available


  13. NARDIN C, Latarche C, Soudant M, Dahan C, et al
    Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study.
    PLoS One. 2018;13:e0194115.
    PubMed     Text format     Abstract available


  14. NOVAKOVA L, Axelsson M, Malmestrom C, Imberg H, et al
    Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
    PLoS One. 2018;13:e0194828.
    PubMed     Text format     Abstract available


  15. KOZIARSKA D, Krol J, Nocon D, Kubaszewski P, et al
    Prevalence and factors leading to unemployment in MS (multiple sclerosis) patients undergoing immunomodulatory treatment in Poland.
    PLoS One. 2018;13:e0194117.
    PubMed     Text format     Abstract available


  16. DE SANTIAGO L, Sanchez-Morla E, Blanco R, Miguel JM, et al
    Empirical mode decomposition processing to improve multifocal-visual-evoked-potential signal analysis in multiple sclerosis.
    PLoS One. 2018;13:e0194964.
    PubMed     Text format     Abstract available


  17. CIURLEO R, Bonanno L, De Salvo S, Romeo L, et al
    Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: An olfactory event related potential study.
    PLoS One. 2018;13:e0196006.
    PubMed     Text format     Abstract available


  18. SANCHEZ-DALMAU B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, et al
    Predictors of vision impairment in Multiple Sclerosis.
    PLoS One. 2018;13:e0195856.
    PubMed     Text format     Abstract available


  19. KLISTORNER A, Wang C, Yiannikas C, Parratt J, et al
    Diffusivity in the core of chronic multiple sclerosis lesions.
    PLoS One. 2018;13:e0194142.
    PubMed     Text format     Abstract available


  20. CHROBOK NL, Bol JGJM, Jongenelen CA, Breve JJP, et al
    Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    PLoS One. 2018;13:e0196433.
    PubMed     Text format     Abstract available


  21. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Schuster T, et al
    Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.
    PLoS One. 2018;13:e0196244.
    PubMed     Text format     Abstract available



  22. Correction: Empirical mode decomposition processing to improve multifocal-visual-evoked-potential signal analysis in multiple sclerosis.
    PLoS One. 2018;13:e0196928.
    PubMed     Text format     Abstract available


  23. STORM FA, Nair KPS, Clarke AJ, Van der Meulen JM, et al
    Free-living and laboratory gait characteristics in patients with multiple sclerosis.
    PLoS One. 2018;13:e0196463.
    PubMed     Text format     Abstract available


  24. FERNANDEZ O, Izquierdo G, Fernandez V, Leyva L, et al
    Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
    PLoS One. 2018;13:e0195891.
    PubMed     Text format     Abstract available


  25. SCOTTI B, Disanto G, Sacco R, Guigli M, et al
    Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
    PLoS One. 2018;13:e0197415.
    PubMed     Text format     Abstract available


  26. MARCK CH, De Livera AM, Brown CR, Neate SL, et al
    Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: Three year follow-up.
    PLoS One. 2018;13:e0197759.
    PubMed     Text format     Abstract available


  27. POTTGEN J, Rose A, van de Vis W, Engelbrecht J, et al
    Sexual dysfunctions in MS in relation to neuropsychiatric aspects and its psychological treatment: A scoping review.
    PLoS One. 2018;13:e0193381.
    PubMed     Text format     Abstract available


  28. ADUSUMILLI G, Lancia S, Levasseur VA, Amblee V, et al
    Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis.
    PLoS One. 2018;13:e0198178.
    PubMed     Text format     Abstract available


    January 2017
  29. MOCCIA M, Palladino R, Lanzillo R, Carotenuto A, et al
    Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.
    PLoS One. 2017;12:e0169489.
    PubMed     Text format     Abstract available


  30. BROCHET B, Deloire MS, Perez P, Loock T, et al
    Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
    PLoS One. 2017;12:e0168834.
    PubMed     Text format     Abstract available


  31. LIBERTINOVA J, Meluzinova E, Tomek A, Horakova D, et al
    Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNbeta.
    PLoS One. 2017;12:e0169957.
    PubMed     Text format     Abstract available


  32. RAFFEL J, Gafson AR, Dahdaleh S, Malik O, et al
    Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    PLoS One. 2017;12:e0169546.
    PubMed     Text format     Abstract available


  33. KAVALIUNAS A, Manouchehrinia A, Danylaite Karrenbauer V, Gyllensten H, et al
    Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    PLoS One. 2017;12:e0169460.
    PubMed     Text format     Abstract available


  34. HURTADO-GUERRERO I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, et al
    Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNss in Multiple Sclerosis Patients According to the Therapeutic Response to IFNss.
    PLoS One. 2017;12:e0170031.
    PubMed     Text format     Abstract available


  35. UECKER FC, Olze H, Kunte H, Gerz C, et al
    Longitudinal Testing of Olfactory and Gustatory Function in Patients with Multiple Sclerosis.
    PLoS One. 2017;12:e0170492.
    PubMed     Text format     Abstract available


  36. ZOU L, Wang H, Xiao Z, Fang Q, et al
    Tai chi for health benefits in patients with multiple sclerosis: A systematic review.
    PLoS One. 2017;12:e0170212.
    PubMed     Text format     Abstract available


  37. MOON Y, McGinnis RS, Seagers K, Motl RW, et al
    Monitoring gait in multiple sclerosis with novel wearable motion sensors.
    PLoS One. 2017;12:e0171346.
    PubMed     Text format     Abstract available


  38. LINK J, Ramanujam R, Auer M, Ryner M, et al
    Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    PLoS One. 2017;12:e0170395.
    PubMed     Text format     Abstract available


  39. MORANDI E, Tanasescu R, Tarlinton RE, Constantinescu CS, et al
    The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0172415.
    PubMed     Text format     Abstract available


  40. BEHBEHANI R, Abu Al-Hassan A, Al-Salahat A, Sriraman D, et al
    Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    PLoS One. 2017;12:e0172120.
    PubMed     Text format     Abstract available


  41. FAIZY TD, Thaler C, Ceyrowski T, Broocks G, et al
    Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period.
    PLoS One. 2017;12:e0172923.
    PubMed     Text format     Abstract available


  42. KOMEGAE EN, Souza TA, Grund LZ, Lima C, et al
    Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0171796.
    PubMed     Text format     Abstract available


  43. WENDEBOURG MJ, Heesen C, Finlayson M, Meyer B, et al
    Patient education for people with multiple sclerosis-associated fatigue: A systematic review.
    PLoS One. 2017;12:e0173025.
    PubMed     Text format     Abstract available


  44. MULS N, Nasr Z, Dang HA, Sindic C, et al
    IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.
    PLoS One. 2017;12:e0173780.
    PubMed     Text format     Abstract available


  45. HEGEN H, Auer M, Bsteh G, Di Pauli F, et al
    Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
    PLoS One. 2017;12:e0174005.
    PubMed     Text format     Abstract available


  46. AYUSO T, Aznar P, Soriano L, Olaskoaga A, et al
    Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis.
    PLoS One. 2017;12:e0174726.
    PubMed     Text format     Abstract available


  47. GIESS RM, Pfuhl C, Behrens JR, Rasche L, et al
    Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.
    PLoS One. 2017;12:e0175279.
    PubMed     Text format     Abstract available


  48. DOBRAKOWSKI P, Bogocz M, Cholewa K, Rajchel M, et al
    Month of birth and level of insolation as risk factors for multiple sclerosis in Poland.
    PLoS One. 2017;12:e0175156.
    PubMed     Text format     Abstract available


  49. ZHAO Y, Healy BC, Rotstein D, Guttmann CR, et al
    Exploration of machine learning techniques in predicting multiple sclerosis disease course.
    PLoS One. 2017;12:e0174866.
    PubMed     Text format     Abstract available


  50. KRAMER J, Tenberge JG, Kleiter I, Gaissmaier W, et al
    Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    PLoS One. 2017;12:e0174858.
    PubMed     Text format     Abstract available


  51. SHARMA S, Zhang Y
    Fourier transform power spectrum is a potential measure of tissue alignment in standard MRI: A multiple sclerosis study.
    PLoS One. 2017;12:e0175979.
    PubMed     Text format     Abstract available


  52. NAVAS-MADRONAL M, Valero-Mut A, Martinez-Zapata MJ, Simon-Talero MJ, et al
    Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.
    PLoS One. 2017;12:e0175538.
    PubMed     Text format     Abstract available


  53. SCHNEIDER R, Bellenberg B, Hoepner R, Kolb EM, et al
    Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    PLoS One. 2017;12:e0176415.
    PubMed     Text format     Abstract available


  54. INGLESE M, Petracca M, Mormina E, Achiron A, et al
    Cerebellar volume as imaging outcome in progressive multiple sclerosis.
    PLoS One. 2017;12:e0176519.
    PubMed     Text format     Abstract available


  55. IZQUIERDO G, Damas F, Paramo MD, Ruiz-Pena JL, et al
    The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
    PLoS One. 2017;12:e0176174.
    PubMed     Text format     Abstract available


  56. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2017;12:e0177177.
    PubMed     Text format     Abstract available


  57. MOLLISON D, Sellar R, Bastin M, Mollison D, et al
    The clinico-radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0177727.
    PubMed     Text format     Abstract available


  58. MCGINNIS RS, Mahadevan N, Moon Y, Seagers K, et al
    A machine learning approach for gait speed estimation using skin-mounted wearable sensors: From healthy controls to individuals with multiple sclerosis.
    PLoS One. 2017;12:e0178366.
    PubMed     Text format     Abstract available


  59. PARDO E, Carcamo C, Uribe-San Martin R, Ciampi E, et al
    Galectin-8 as an immunosuppressor in experimental autoimmune encephalomyelitis and a target of human early prognostic antibodies in multiple sclerosis.
    PLoS One. 2017;12:e0177472.
    PubMed     Text format     Abstract available


  60. LANDI D, Albanese M, Buttari F, Monteleone F, et al
    Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    PLoS One. 2017;12:e0165415.
    PubMed     Text format     Abstract available


  61. RIGHART R, Schmidt P, Dahnke R, Biberacher V, et al
    Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients.
    PLoS One. 2017;12:e0179590.
    PubMed     Text format     Abstract available


  62. BERNITSAS E, Khan O, Razmjou S, Tselis A, et al
    Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.
    PLoS One. 2017;12:e0181431.
    PubMed     Text format     Abstract available


  63. ITOH Y, Voskuhl RR
    Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
    PLoS One. 2017;12:e0181349.
    PubMed     Text format     Abstract available


  64. BSTEH G, Ehling R, Walchhofer LM, Hegen H, et al
    Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II study.
    PLoS One. 2017;12:e0181458.
    PubMed     Text format     Abstract available


  65. KIM HH, Jeong IH, Hyun JS, Kong BS, et al
    Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance.
    PLoS One. 2017;12:e0181758.
    PubMed     Text format     Abstract available


  66. WURTH S, Kuenz B, Bsteh G, Ehling R, et al
    Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.
    PLoS One. 2017;12:e0182462.
    PubMed     Text format     Abstract available


  67. MESSINA S, Solaro C, Righini I, Bergamaschi R, et al
    Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
    PLoS One. 2017;12:e0180651.
    PubMed     Text format     Abstract available


  68. ABDELHAK A, Hottenrott T, Mayer C, Hintereder G, et al
    CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.
    PLoS One. 2017;12:e0182647.
    PubMed     Text format     Abstract available


  69. THALER C, Schneider T, Sedlacik J, Kutzner D, et al
    T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis.
    PLoS One. 2017;12:e0183099.
    PubMed     Text format     Abstract available


  70. MODICA CM, Schweser F, Sudyn ML, Bertolino N, et al
    Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0182729.
    PubMed     Text format     Abstract available


  71. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Microstructural analyses of the posterior cerebellar lobules in relapsing-onset multiple sclerosis and their implication in cognitive impairment.
    PLoS One. 2017;12:e0182479.
    PubMed     Text format     Abstract available


  72. CEUNINCK VAN CAPELLE A, Meide HV, Vosman FJH, Visser LH, et al
    A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS).
    PLoS One. 2017;12:e0182806.
    PubMed     Text format     Abstract available


  73. PUTHENPARAMPIL M, Federle L, Poggiali D, Miante S, et al
    Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis.
    PLoS One. 2017;12:e0183957.
    PubMed     Text format     Abstract available


  74. MASUDA H, Hirano S, Takahashi N, Hatsugano E, et al
    Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder.
    PLoS One. 2017;12:e0184012.
    PubMed     Text format     Abstract available


  75. PARK HY, Park JW, Song HJ, Sohn HS, et al
    The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea.
    PLoS One. 2017;12:e0169463.
    PubMed     Text format     Abstract available


  76. TALMAGE GD, Coppes OJM, Javed A, Bernard J, et al
    Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.
    PLoS One. 2017;12:e0173299.
    PubMed     Text format     Abstract available


  77. ZAPRUTKO T, Kopciuch D, Kus K, Merks P, et al
    Affordability of medicines in the European Union.
    PLoS One. 2017;12:e0172753.
    PubMed     Text format     Abstract available


  78. PAUZUOLIS M, Eich T, Burman J
    Quantification of gammadelta T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.
    PLoS One. 2017;12:e0179095.
    PubMed     Text format     Abstract available


  79. CHAMI M, Halmer R, Schnoeder L, Anne Becker K, et al
    Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination.
    PLoS One. 2017;12:e0178622.
    PubMed     Text format     Abstract available


  80. ALSOP J, Medin J, Cornelissen C, Vormfelde SV, et al
    Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
    PLoS One. 2017;12:e0173353.
    PubMed     Text format     Abstract available


  81. TAKAYASU L, Suda W, Watanabe E, Fukuda S, et al
    A 3-dimensional mathematical model of microbial proliferation that generates the characteristic cumulative relative abundance distributions in gut microbiomes.
    PLoS One. 2017;12:e0180863.
    PubMed     Text format     Abstract available


  82. JONAS SF, Mbogning C, Hassler S, Broet P, et al
    A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology.
    PLoS One. 2017;12:e0179896.
    PubMed     Text format     Abstract available


  83. KIDD T, Carey N, Mold F, Westwood S, et al
    A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life.
    PLoS One. 2017;12:e0185931.
    PubMed     Text format     Abstract available


  84. FERNANDEZ O, Duran E, Ayuso T, Hernandez L, et al
    Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
    PLoS One. 2017;12:e0185766.
    PubMed     Text format     Abstract available


  85. FAVARETTO A, Lazzarotto A, Riccardi A, Pravato S, et al
    Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis.
    PLoS One. 2017;12:e0185626.
    PubMed     Text format     Abstract available


  86. BESELER C, Vollmer T, Graner M, Yu X, et al
    The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution.
    PLoS One. 2017;12:e0186842.
    PubMed     Text format     Abstract available


  87. RAKNES G, Smabrekke L
    Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.
    PLoS One. 2017;12:e0187423.
    PubMed     Text format     Abstract available


  88. WYBRECHT D, Reuter F, Pariollaud F, Zaaraoui W, et al
    New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study.
    PLoS One. 2017;12:e0184650.
    PubMed     Text format     Abstract available


  89. LIU S, Liu X, Chen S, Xiao Y, et al
    Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
    PLoS One. 2017;12:e0188644.
    PubMed     Text format     Abstract available


  90. MOISSET X, Perie M, Pereira B, Dumont E, et al
    Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.
    PLoS One. 2017;12:e0188120.
    PubMed     Text format     Abstract available


  91. GROBELNY A, Behrens JR, Mertens S, Otte K, et al
    Maximum walking speed in multiple sclerosis assessed with visual perceptive computing.
    PLoS One. 2017;12:e0189281.
    PubMed     Text format     Abstract available


  92. WEN J, Yablonskiy DA, Salter A, Cross AH, et al
    Limbic system damage in MS: MRI assessment and correlations with clinical testing.
    PLoS One. 2017;12:e0187915.
    PubMed     Text format     Abstract available


  93. CHEN Y, Zhen W, Guo T, Zhao Y, et al
    Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination.
    PLoS One. 2017;12:e0189380.
    PubMed     Text format     Abstract available


    January 2016
  94. AKBAR N, Giorgio A, Till C, Sled JG, et al
    Alterations in Functional and Structural Connectivity in Pediatric-Onset Multiple Sclerosis.
    PLoS One. 2016;11:e0145906.
    PubMed     Text format     Abstract available


  95. ZHOU F, Zhuang Y, Gong H, Zhan J, et al
    Resting State Brain Entropy Alterations in Relapsing Remitting Multiple Sclerosis.
    PLoS One. 2016;11:e0146080.
    PubMed     Text format     Abstract available


  96. KIISKI HS, Ni Riada S, Lalor EC, Goncalves NR, et al
    Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis.
    PLoS One. 2016;11:e0146084.
    PubMed     Text format     Abstract available


  97. NIELSEN CH, Bornsen L, Sellebjerg F, Brimnes MK, et al
    Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-alpha and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2016;11:e0146971.
    PubMed     Text format     Abstract available


  98. POPESCU V, Schoonheim MM, Versteeg A, Chaturvedi N, et al
    Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method.
    PLoS One. 2016;11:e0143942.
    PubMed     Text format     Abstract available


  99. SHINTO L, Marracci G, Mohr DC, Bumgarner L, et al
    Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study.
    PLoS One. 2016;11:e0147195.
    PubMed     Text format     Abstract available


  100. RODIC SZ, Knezevic TI, Kisic-Tepavcevic DB, Dackovic JR, et al
    Validation of the Serbian Version of Multiple Sclerosis Spasticity Scale 88 (MSSS-88).
    PLoS One. 2016;11:e0147042.
    PubMed     Text format     Abstract available


  101. RASCHE L, Heiserich L, Behrens JR, Lenz K, et al
    Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study.
    PLoS One. 2016;11:e0147968.
    PubMed     Text format     Abstract available


  102. MARCK CH, Neate SL, Taylor KL, Weiland TJ, et al
    Prevalence of Comorbidities, Overweight and Obesity in an International Sample of People with Multiple Sclerosis and Associations with Modifiable Lifestyle Factors.
    PLoS One. 2016;11:e0148573.
    PubMed     Text format     Abstract available


  103. TSCHOCHNER M, Leary S, Cooper D, Strautins K, et al
    Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.
    PLoS One. 2016;11:e0147567.
    PubMed     Text format     Abstract available


  104. MOTTA C, Palermo E, Studer V, Germanotta M, et al
    Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis.
    PLoS One. 2016;11:e0148997.
    PubMed     Text format     Abstract available


  105. AN H, Lim C, Guillemin GJ, Vollmer-Conna U, et al
    Serum Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) Is Increased in Patients with Multiple Sclerosis and Is a Strong Independent Indicator of Disease Severity; 6.7kbp LILRA3 Gene Deletion Is Not Associated with Diseases Susceptibility.
    PLoS One. 2016;11:e0149200.
    PubMed     Text format     Abstract available


  106. KLISTORNER A, Wang C, Yiannikas C, Graham SL, et al
    Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study.
    PLoS One. 2016;11:e0149245.
    PubMed     Text format     Abstract available


  107. ZAINI WH, Giuliani F, Beaulieu C, Kalra S, et al
    Fatigue in Multiple Sclerosis: Assessing Pontine Involvement Using Proton MR Spectroscopic Imaging.
    PLoS One. 2016;11:e0149622.
    PubMed     Text format     Abstract available


  108. MOUZAKI A, Rodi M, Dimisianos N, Emmanuil A, et al
    Correction: Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    PLoS One. 2016;11:e0151411.
    PubMed     Text format     Abstract available


  109. HELLWIG K, Chen LH, Stancyzk FZ, Langer-Gould AM, et al
    Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility.
    PLoS One. 2016;11:e0149094.
    PubMed     Text format     Abstract available


  110. FAIZY TD, Thaler C, Kumar D, Sedlacik J, et al
    Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging.
    PLoS One. 2016;11:e0151496.
    PubMed     Text format     Abstract available


  111. CHEVALIER J, Chamoux C, Hammes F, Chicoye A, et al
    Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    PLoS One. 2016;11:e0150703.
    PubMed     Text format     Abstract available


  112. BRANGER P, Parienti JJ, Sormani MP, Defer G, et al
    The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.
    PLoS One. 2016;11:e0149685.
    PubMed     Text format     Abstract available


  113. PINTER D, Beckmann C, Koini M, Pirker E, et al
    Reproducibility of Resting State Connectivity in Patients with Stable Multiple Sclerosis.
    PLoS One. 2016;11:e0152158.
    PubMed     Text format     Abstract available


  114. DISANTO G, Benkert P, Lorscheider J, Mueller S, et al
    The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
    PLoS One. 2016;11:e0152347.
    PubMed     Text format     Abstract available


  115. KUSPINAR A, Pickard S, Mayo NE
    Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale.
    PLoS One. 2016;11:e0151905.
    PubMed     Text format     Abstract available


  116. BEGGS CB, Magnano C, Belov P, Krawiecki J, et al
    Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.
    PLoS One. 2016;11:e0153960.
    PubMed     Text format     Abstract available


  117. LAIBLE M, Jarius S, Mackensen F, Schmidt-Bacher A, et al
    Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0155322.
    PubMed     Text format     Abstract available


  118. MASSA MG, Gisevius B, Hirschberg S, Hinz L, et al
    Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells.
    PLoS One. 2016;11:e0155274.
    PubMed     Text format     Abstract available


  119. DORONIN VB, Parkhomenko TA, Castellazzi M, Cesnik E, et al
    Comparison of Antibodies with Amylase Activity from Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0154688.
    PubMed     Text format     Abstract available


  120. STAMILE C, Kocevar G, Cotton F, Durand-Dubief F, et al
    A Sensitive and Automatic White Matter Fiber Tracts Model for Longitudinal Analysis of Diffusion Tensor Images in Multiple Sclerosis.
    PLoS One. 2016;11:e0156405.
    PubMed     Text format     Abstract available


  121. KARAMYAN A, Dunser MW, Wiebe DJ, Pilz G, et al
    Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study.
    PLoS One. 2016;11:e0155795.
    PubMed     Text format     Abstract available


  122. MURIS AH, Smolders J, Rolf L, Klinkenberg LJ, et al
    Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.
    PLoS One. 2016;11:e0156122.
    PubMed     Text format     Abstract available


  123. PLAISTED WC, Zavala A, Hingco E, Tran H, et al
    Remyelination Is Correlated with Regulatory T Cell Induction Following Human Embryoid Body-Derived Neural Precursor Cell Transplantation in a Viral Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0157620.
    PubMed     Text format     Abstract available


  124. BOUDARHAM J, Hameau S, Zory R, Hardy A, et al
    Coactivation of Lower Limb Muscles during Gait in Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0158267.
    PubMed     Text format     Abstract available


  125. SATUE M, Rodrigo MJ, Otin S, Bambo MP, et al
    Relationship between Visual Dysfunction and Retinal Changes in Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0157293.
    PubMed     Text format     Abstract available


  126. D'AMICO E, Leone C, Graziano G, Amato MP, et al
    The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.
    PLoS One. 2016;11:e0157721.
    PubMed     Text format     Abstract available


  127. BSTEH G, Ehling R, Lutterotti A, Hegen H, et al
    Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.
    PLoS One. 2016;11:e0158978.
    PubMed     Text format     Abstract available


  128. PAOLICELLI D, Iannazzo S, Santoni L, Iaffaldano A, et al
    The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
    PLoS One. 2016;11:e0159214.
    PubMed     Text format     Abstract available


  129. KREMER D, Cui QL, Gottle P, Kuhlmann T, et al
    CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
    PLoS One. 2016;11:e0146503.
    PubMed     Text format     Abstract available


  130. ERNSTSSON O, Gyllensten H, Alexanderson K, Tinghog P, et al
    Cost of Illness of Multiple Sclerosis - A Systematic Review.
    PLoS One. 2016;11:e0159129.
    PubMed     Text format     Abstract available


  131. BONNIER G, Kober T, Schluep M, Du Pasquier R, et al
    A New Approach for Deep Gray Matter Analysis Using Partial-Volume Estimation.
    PLoS One. 2016;11:e0148631.
    PubMed     Text format     Abstract available


  132. WIENDL H, Butzkueven H, Kappos L, Trojano M, et al
    Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
    PLoS One. 2016;11:e0144834.
    PubMed     Text format     Abstract available


  133. RASENACK M, Rychen J, Andelova M, Naegelin Y, et al
    Efficacy and Safety of Fingolimod in an Unselected Patient Population.
    PLoS One. 2016;11:e0146190.
    PubMed     Text format     Abstract available


  134. DAVIES JL, Thompson S, Kaur-Sandhu H, Sawcer S, et al
    Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis.
    PLoS One. 2016;11:e0158327.
    PubMed     Text format     Abstract available


  135. DENNISON L, McCloy Smith E, Bradbury K, Galea I, et al
    How Do People with Multiple Sclerosis Experience Prognostic Uncertainty and Prognosis Communication? A Qualitative Study.
    PLoS One. 2016;11:e0158982.
    PubMed     Text format     Abstract available


  136. DAHL LC, Nasa Z, Chung J, Niego B, et al
    The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.
    PLoS One. 2016;11:e0158653.
    PubMed     Text format     Abstract available


  137. GILLI F, Chen X, Pachner AR, Gimi B, et al
    High-Resolution Diffusion Tensor Spinal Cord MRI Measures as Biomarkers of Disability Progression in a Rodent Model of Progressive Multiple Sclerosis.
    PLoS One. 2016;11:e0160071.
    PubMed     Text format     Abstract available


  138. SALEHI Z, Doosti R, Beheshti M, Janzamin E, et al
    Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns.
    PLoS One. 2016;11:e0159565.
    PubMed     Text format     Abstract available


  139. MARTIN JE, Raffel J, Nicholas R
    Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care.
    PLoS One. 2016;11:e0159210.
    PubMed     Text format     Abstract available


  140. IANNETTA M, Zingaropoli MA, Bellizzi A, Morreale M, et al
    Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    PLoS One. 2016;11:e0160277.
    PubMed     Text format     Abstract available


  141. HAREL A, Ceccarelli A, Farrell C, Fabian M, et al
    Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS.
    PLoS One. 2016;11:e0152180.
    PubMed     Text format     Abstract available


  142. GRACIEN RM, Jurcoane A, Wagner M, Reitz SC, et al
    The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis.
    PLoS One. 2016;11:e0161036.
    PubMed     Text format     Abstract available


  143. FERNANDEZ O, Arroyo R, Martinez-Yelamos S, Marco M, et al
    Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart(R) Device in Patients with Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2016;11:e0160313.
    PubMed     Text format     Abstract available


  144. JELINEK GA, De Livera AM, Marck CH, Brown CR, et al
    Associations of Lifestyle, Medication, and Socio-Demographic Factors with Disability in People with Multiple Sclerosis: An International Cross-Sectional Study.
    PLoS One. 2016;11:e0161701.
    PubMed     Text format     Abstract available


  145. ROSATO R, Testa S, Bertolotto A, Confalonieri P, et al
    Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory.
    PLoS One. 2016;11:e0153466.
    PubMed     Text format     Abstract available


  146. OBERT D, Helms G, Sattler MB, Jung K, et al
    Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    PLoS One. 2016;11:e0162583.
    PubMed     Text format     Abstract available


  147. SOLARO C, Trabucco E, Signori A, Martinelli V, et al
    Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory.
    PLoS One. 2016;11:e0160261.
    PubMed     Text format     Abstract available


  148. TSIVGOULIS G, Katsanos AH, Mavridis D, Grigoriadis N, et al
    The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
    PLoS One. 2016;11:e0163296.
    PubMed     Text format     Abstract available


  149. MONTI MC, Guido D, Montomoli C, Sardu C, et al
    Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia.
    PLoS One. 2016;11:e0163313.
    PubMed     Text format     Abstract available


  150. JERNAS L, Wencel J, Wiak A, Bieniek M, et al
    Risk Factors for Poor Adherence to Betaferon(R) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.
    PLoS One. 2016;11:e0157950.
    PubMed     Text format     Abstract available


  151. KAUSHIK DK, Yong HY, Hahn JN, Silva C, et al
    Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.
    PLoS One. 2016;11:e0163802.
    PubMed     Text format     Abstract available


  152. RIEMANN-LORENZ K, Eilers M, von Geldern G, Schulz KH, et al
    Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program.
    PLoS One. 2016;11:e0165246.
    PubMed     Text format     Abstract available


  153. KALRON A, Givon U, Frid L, Dolev M, et al
    Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis.
    PLoS One. 2016;11:e0164467.
    PubMed     Text format     Abstract available


  154. HAJIEBRAHIMI M, Montgomery S, Burkill S, Bahmanyar S, et al
    Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients.
    PLoS One. 2016;11:e0165027.
    PubMed     Text format     Abstract available


  155. KREMER IE, Evers SM, Jongen PJ, van der Weijden T, et al
    Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.
    PLoS One. 2016;11:e0164862.
    PubMed     Text format     Abstract available


  156. BACHELET D, Hassler S, Mbogning C, Link J, et al
    Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
    PLoS One. 2016;11:e0162752.
    PubMed     Text format     Abstract available


  157. ALROUGHANI R, Akhtar S, Ahmed S, Behbehani R, et al
    Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
    PLoS One. 2016;11:e0165846.
    PubMed     Text format     Abstract available


  158. DOBSON R, Ramagopalan S, Topping J, Smith P, et al
    A Risk Score for Predicting Multiple Sclerosis.
    PLoS One. 2016;11:e0164992.
    PubMed     Text format     Abstract available


  159. ZHANG L, Wang L, Tian P, Tian S, et al
    Identification of Genes Discriminating Multiple Sclerosis Patients from Controls by Adapting a Pathway Analysis Method.
    PLoS One. 2016;11:e0165543.
    PubMed     Text format     Abstract available


  160. MARTIN P, McGovern A, Massey J, Schoenfelder S, et al
    Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C.
    PLoS One. 2016;11:e0166923.
    PubMed     Text format     Abstract available


  161. JOHNSON TW, Wu Y, Nathoo N, Rogers JA, et al
    Gray Matter Hypoxia in the Brain of the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0167196.
    PubMed     Text format     Abstract available


  162. PIVOT D, Debouverie M, Grzebyk M, Brassat D, et al
    Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.
    PLoS One. 2016;11:e0167556.
    PubMed     Text format     Abstract available


  163. PROSPERINI L, de Rossi N, Scarpazza C, Moiola L, et al
    Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    PLoS One. 2016;11:e0168376.
    PubMed     Text format     Abstract available


  164. BLOCK VA, Pitsch E, Tahir P, Cree BA, et al
    Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
    PLoS One. 2016;11:e0154335.
    PubMed     Text format     Abstract available


    January 2015
  165. NATHOO N, Rogers JA, Yong VW, Dunn JF, et al
    Detecting deoxyhemoglobin in spinal cord vasculature of the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis using susceptibility MRI and hyperoxygenation.
    PLoS One. 2015;10:e0127033.
    PubMed     Text format     Abstract available


  166. AKKAD DA, Olischewsky A, Reiner F, Hellwig K, et al
    Combinations of susceptibility genes are associated with higher risk for multiple sclerosis and imply disease course specificity.
    PLoS One. 2015;10:e0127632.
    PubMed     Text format     Abstract available


  167. HYUN JW, Kim SH, Jeong IH, Ahn SW, et al
    Utility of the rio score and modified rio score in korean patients with multiple sclerosis.
    PLoS One. 2015;10:e0129243.
    PubMed     Text format     Abstract available


  168. FAVARETTO A, Poggiali D, Lazzarotto A, Rolma G, et al
    The Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset.
    PLoS One. 2015;10:e0127805.
    PubMed     Text format     Abstract available


  169. TOLLEY K, Hutchinson M, You X, Wang P, et al
    A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2015;10:e0127960.
    PubMed     Text format     Abstract available


  170. TEJERA-ALHAMBRA M, Casrouge A, de Andres C, Seyfferth A, et al
    Plasma biomarkers discriminate clinical forms of multiple sclerosis.
    PLoS One. 2015;10:e0128952.
    PubMed     Text format     Abstract available


  171. DEL PICCOLO L, Pietrolongo E, Radice D, Tortorella C, et al
    Patient expression of emotions and neurologist responses in first multiple sclerosis consultations.
    PLoS One. 2015;10:e0127734.
    PubMed     Text format     Abstract available


  172. SOLTI I, Kvell K, Talaber G, Veto S, et al
    Thymic Atrophy and Apoptosis of CD4+CD8+ Thymocytes in the Cuprizone Model of Multiple Sclerosis.
    PLoS One. 2015;10:e0129217.
    PubMed     Text format     Abstract available


  173. PERGA S, Giuliano Albo A, Lis K, Minari N, et al
    Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis.
    PLoS One. 2015;10:e0129291.
    PubMed     Text format     Abstract available


  174. VAN DER HIELE K, van Gorp D, Ruimschotel R, Kamminga N, et al
    Work Participation and Executive Abilities in Patients with Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2015;10:e0129228.
    PubMed     Text format     Abstract available


  175. MALYAVANTHAM K, Weinstock-Guttman B, Suresh L, Zivadinov R, et al
    Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.
    PLoS One. 2015;10:e0129503.
    PubMed     Text format     Abstract available


  176. MANCUSO R, Hernis A, Agostini S, Rovaris M, et al
    Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis.
    PLoS One. 2015;10:e0130715.
    PubMed     Text format     Abstract available


  177. ZHUANG Y, Zhou F, Gong H
    Intrinsic Functional Plasticity of the Sensorimotor Network in Relapsing-Remitting Multiple Sclerosis: Evidence from a Centrality Analysis.
    PLoS One. 2015;10:e0130524.
    PubMed     Text format     Abstract available


  178. AL-SHAMMRI SN, Hanna MG, Chattopadhyay A, Akanji AO, et al
    Sociocultural and Demographic Risk Factors for the Development of Multiple Sclerosis in Kuwait: A Case - Control Study.
    PLoS One. 2015;10:e0132106.
    PubMed     Text format     Abstract available


  179. ALLIZOND V, Scutera S, Rossi S, Musso T, et al
    Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data.
    PLoS One. 2015;10:e0131557.
    PubMed     Text format     Abstract available


  180. LERAY E, Vukusic S, Debouverie M, Clanet M, et al
    Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.
    PLoS One. 2015;10:e0132033.
    PubMed     Text format     Abstract available


  181. BOZIN I, Ge Y, Kuchling J, Dusek P, et al
    Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
    PLoS One. 2015;10:e0128386.
    PubMed     Text format     Abstract available


  182. LEIKFOSS IS, Keshari PK, Gustavsen MW, Bjolgerud A, et al
    Multiple Sclerosis Risk Allele in CLEC16A Acts as an Expression Quantitative Trait Locus for CLEC16A and SOCS1 in CD4+ T Cells.
    PLoS One. 2015;10:e0132957.
    PubMed     Text format     Abstract available


  183. FAN X, Jin T, Zhao S, Liu C, et al
    Circulating CCR7+ICOS+ Memory T Follicular Helper Cells in Patients with Multiple Sclerosis.
    PLoS One. 2015;10:e0134523.
    PubMed     Text format     Abstract available


  184. HANSEN K, Schussel K, Kieble M, Werning J, et al
    Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
    PLoS One. 2015;10:e0133279.
    PubMed     Text format     Abstract available


  185. SEVERIJNS D, Octavia JR, Kerkhofs L, Coninx K, et al
    Investigation of Fatigability during Repetitive Robot-Mediated Arm Training in People with Multiple Sclerosis.
    PLoS One. 2015;10:e0133729.
    PubMed     Text format     Abstract available


  186. EHLER J, Koball S, Sauer M, Mitzner S, et al
    Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.
    PLoS One. 2015;10:e0134583.
    PubMed     Text format     Abstract available


  187. CALABRESE M, Reynolds R, Magliozzi R, Castellaro M, et al
    Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0135428.
    PubMed     Text format     Abstract available


  188. BERTOLI D, Serana F, Sottini A, Cordioli C, et al
    Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
    PLoS One. 2015;10:e0135441.
    PubMed     Text format     Abstract available


  189. NYGAARD GO, Celius EG, de Rodez Benavent SA, Sowa P, et al
    A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.
    PLoS One. 2015;10:e0135974.
    PubMed     Text format     Abstract available


  190. ORTIZ MA, Nunez C, Ordonez D, Alvarez-Cermeno JC, et al
    Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.
    PLoS One. 2015;10:e0134414.
    PubMed     Text format     Abstract available


  191. LOPEZ-GONGORA M, Escartin A, Martinez-Horta S, Fernandez-Bobadilla R, et al
    Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis.
    PLoS One. 2015;10:e0136786.
    PubMed     Text format     Abstract available


  192. MOUZAKI A, Rodi M, Dimisianos N, Emmanuil A, et al
    Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    PLoS One. 2015;10:e0135434.
    PubMed     Text format     Abstract available


  193. MATTHEWS L, Kolind S, Brazier A, Leite MI, et al
    Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.
    PLoS One. 2015;10:e0137715.
    PubMed     Text format     Abstract available


  194. MIYAKE S, Kim S, Suda W, Oshima K, et al
    Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters.
    PLoS One. 2015;10:e0137429.
    PubMed     Text format     Abstract available


  195. ZIEMSSEN T, Rauer S, Stadelmann C, Henze T, et al
    Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review.
    PLoS One. 2015;10:e0138243.
    PubMed     Text format     Abstract available


  196. WENS I, Dalgas U, Vandenabeele F, Grevendonk L, et al
    High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise Capacity, a Randomised Controlled Trial.
    PLoS One. 2015;10:e0133697.
    PubMed     Text format     Abstract available


  197. CHOI JH, Lee MJ, Jang M, Kim EJ, et al
    An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
    PLoS One. 2015;10:e0138592.
    PubMed     Text format     Abstract available


  198. HADJIGEORGIOU G, Dardiotis E, Tsivgoulis G, Doskas T, et al
    Correction: Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).
    PLoS One. 2015;10:e0140308.
    PubMed     Text format     Abstract available


  199. HEESEN C, Kasper J, Fischer K, Kopke S, et al
    Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0) - Development of an Outcome Instrument for Educational Interventions.
    PLoS One. 2015;10:e0138364.
    PubMed     Text format     Abstract available


  200. BERG S, Kaschka I, Utz KS, Huhn K, et al
    Baseline magnetic resonance imaging of the optic nerve provides limited predictive information on short-term recovery after acute optic neuritis.
    PLoS One. 2015;10:e0113961.
    PubMed     Text format     Abstract available


  201. NIELSEN HH, Beck HC, Kristensen LP, Burton M, et al
    The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study.
    PLoS One. 2015;10:e0139659.
    PubMed     Text format     Abstract available



  202. Correction: An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
    PLoS One. 2015;10:e0141635.
    PubMed     Text format     Abstract available


  203. JONKMAN LE, Rosenthal DM, Sormani MP, Miles L, et al
    Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis.
    PLoS One. 2015;10:e0129380.
    PubMed     Text format     Abstract available


  204. SAMUVEL DJ, Saxena N, Dhindsa JS, Singh AK, et al
    AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
    PLoS One. 2015;10:e0141781.
    PubMed     Text format     Abstract available


  205. AL-TEMAIMI RA, Al-Enezi A, Al-Serri A, Al-Roughani R, et al
    The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait.
    PLoS One. 2015;10:e0142265.
    PubMed     Text format     Abstract available


  206. BESTER M, Forkert ND, Stellmann JP, Sturner K, et al
    Correction: Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0142464.
    PubMed     Text format     Abstract available


  207. LAMARGUE HAMEL D, Deloire M, Ruet A, Charre-Morin J, et al
    Deciphering Depressive Mood in Relapsing-Remitting and Progressive Multiple Sclerosis and Its Consequence on Quality of Life.
    PLoS One. 2015;10:e0142152.
    PubMed     Text format     Abstract available


  208. ABOULENEIN-DJAMSHIDIAN F, Krssak M, Serbecic N, Rauschka H, et al
    CROP - The Clinico-Radiologico-Ophthalmological Paradox in Multiple Sclerosis: Are Patterns of Retinal and MRI Changes Heterogeneous and Thus Not Predictable?
    PLoS One. 2015;10:e0142272.
    PubMed     Text format     Abstract available


  209. MAKSHAKOV G, Nazarov V, Kochetova O, Surkova E, et al
    Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis.
    PLoS One. 2015;10:e0143375.
    PubMed     Text format     Abstract available


  210. KANNEL K, Alnek K, Vahter L, Gross-Paju K, et al
    Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
    PLoS One. 2015;10:e0143393.
    PubMed     Text format     Abstract available


  211. VAN NOORT JM, Bsibsi M, Nacken PJ, Verbeek R, et al
    Therapeutic Intervention in Multiple Sclerosis with Alpha B-Crystallin: A Randomized Controlled Phase IIa Trial.
    PLoS One. 2015;10:e0143366.
    PubMed     Text format     Abstract available



  212. Correction: The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait.
    PLoS One. 2015;10:e0144565.
    PubMed     Text format     Abstract available


  213. VARGA BE, Gao W, Laurik KL, Tatrai E, et al
    Investigating Tissue Optical Properties and Texture Descriptors of the Retina in Patients with Multiple Sclerosis.
    PLoS One. 2015;10:e0143711.
    PubMed     Text format     Abstract available


  214. TSIVGOULIS G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, et al
    The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0144538.
    PubMed     Text format     Abstract available


  215. THALER C, Faizy T, Sedlacik J, Holst B, et al
    T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0144693.
    PubMed     Text format     Abstract available


  216. KAVALIUNAS A, Wiberg M, Tinghog P, Glaser A, et al
    Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0145435.
    PubMed     Text format     Abstract available


  217. STELLMANN JP, Sturner KH, Young KL, Siemonsen S, et al
    Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?
    PLoS One. 2015;10:e0116559.
    PubMed     Text format     Abstract available


  218. GEVAERT T, Moles Lopez X, Sagaert X, Libbrecht L, et al
    Morphometric and quantitative immunohistochemical analysis of disease-related changes in the upper (suburothelial) lamina propria of the human bladder dome.
    PLoS One. 2015;10:e0127020.
    PubMed     Text format     Abstract available


  219. RAKUSA M, Cano SJ, Porter B, Riazi A, et al
    A predictive model for corticosteroid response in individual patients with MS relapses.
    PLoS One. 2015;10:e0120829.
    PubMed     Text format     Abstract available


  220. RIBBONS KA, McElduff P, Boz C, Trojano M, et al
    Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
    PLoS One. 2015;10:e0122686.
    PubMed     Text format     Abstract available


  221. CRUZ Y, Lorea J, Mestre H, Kim-Lee JH, et al
    Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
    PLoS One. 2015;10:e0121854.
    PubMed     Text format     Abstract available


  222. MATTIOLI F, Stampatori C, Bellomi F, Scarpazza C, et al
    Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
    PLoS One. 2015;10:e0131803.
    PubMed     Text format     Abstract available


    January 2014
  223. NOURI M, Bredberg A, Westrom B, Lavasani S, et al
    Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells.
    PLoS One. 2014;9:e106335.
    PubMed     Text format     Abstract available


  224. JONES KH, Jones PA, Middleton RM, Ford DV, et al
    Physical Disability, Anxiety and Depression in People with MS: An Internet-Based Survey via the UK MS Register.
    PLoS One. 2014;9:e104604.
    PubMed     Text format     Abstract available


  225. PRESSLAUER S, Milosavljevic D, Huebl W, Parigger S, et al
    Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.
    PLoS One. 2014;9:e89945.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: